Roche’s Vabysmo matches Regeneron’s Eylea in macular edemaClinical Trials, R&DTwo Phase III trials of Genentech (Roche)’s Vabysmo hit the primary endpoint in macular edema caused by branch and central retinal vein occlusion (BRVO), showing non-inferiority to Regeneron’s Eylea. Read more October 27, 2022/by BioSpace https://www.pharmalive.com/wp-content/uploads/2021/07/Genentechs-Combo-Therapy-for-Rare-Blood-Cancers-Scores-Breakthrough-Designation-BioSpace-7-21-21.jpeg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2022-10-27 11:34:042022-10-27 11:34:04Roche’s Vabysmo matches Regeneron’s Eylea in macular edema
